ACR 0.00% 6.7¢ acrux limited

Ann: Acrux confirms patent challenge, page-11

  1. 5,966 Posts.
    lightbulb Created with Sketch. 50
    well so far all the court cases seem to last years for resolution. Take our Jublia Generic for example.......... ANDA filed 2017(?) orange book...... court case 2018ish, where we in 2022 still don't know the outcome....... even though the US FDA has given us approval for our Jublia Generic ( as well as some 10 others) but ACR cannot launch the product. So if Dapsone follows the same path it'll be 2030 before we are even told how it went.
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.